CD34 Selected Allogeneic HCT w/ Myeloablative Conditionin... | NCT04151706

NCT04151706

ID	Type	Description	Link
BMT339	Other Identifier	OnCore
IRB-49023	Other Identifier	Stanford IRB
P01CA049605	U.S. NIH Grant/Contract		View source

Status Module

Name	Class
National Institutes of Health (NIH)	NIH
National Cancer Institute (NCI)	NIH

Description Module

Label	Type	Description	Intervention Names
fTBI/Thiotepa/fludarabine	Experimental	Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide.	Drug: CD8+ Memory T Cell Infusion Drug: Thiotepa Drug: Fludarabine Radiation: Hyperfractionated TBI Drug: Busulfan Drug: Cyclophosphamide

Name	Type	Description	Arm Group Labels	Other Names
CD8+ Memory T Cell Infusion	Drug	Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation	fTBI/Thiotepa/fludarabine

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Number of Participants Achieving Graft-versus-Host Disease-Free and Relapse-Free Survival (GRFS) Through 1 Year Post-Transplant	The rate of participants who do not experience GvHD and also do not experience relapse are collectively considered to be GRFS. Relapse will be assessed according to the myelodysplastic syndrome or leukemia response criteria. The participants will be assessed for GRFS though 1 year post transplant. The outcome will be reported as the number of participants, a number without dispersion.	1 year

Secondary Outcomes

Measure	Description	Time Frame
Number of Participants Experiencing Graft Rejection Through 1 Year Post-Transplant	Graft rejection will be determined on the basis of reaction against the donor hematopoietic cells. The outcome will be reported as the number of participants who experience graft rejection though 1 year post transplant, a number without dispersion	1 year

Eligibility Module

Eligibility Criteria

Recipient Inclusion Criteria:

Acute leukemia, in morphologic complete remission, OR myelodysplasia with < 10% blasts in the marrow, and no circulating blasts that contain auer rods. Patients with chronic myelomonocytic leukemia (CMML) must have a WBC count ≤ 10,000 cells/μL and < 10% blasts in the marrow.
Planned myeloablative conditioning regimen at Stanford University Medical Center.
Karnofsky or Lansky Performance Score ≥ 70%.
Must have an HLA related donor as follows: onor must be an 8/8 match for HLA A, B and C at intermediate (or higher) resolution, and DRB1 at high resolution using DNA based typing. The donors must be willing to receive G CSF followed by collection of cells by apheresis, and must meet the Program's criteria for donation.
Cardiac function: Ejection fraction at rest ≥ 40%.
Serum creatinine value of < 1.5 mg/dL, or an estimated creatinine clearance greater than 50 mL/minute (using the Stanford calculator for eGFR available in EPIC)
Diffusing capacity of the lungs for carbon monoxide (DLCO) ≥ 50% (adjusted for Hgb)
Forced vital capacity (FVC) ≥ 50%.
Forced expiratory volume (FEV1) ≥ 50%.
Total bilirubin < 2 times the upper limit of normal (ULN) (unless the elevated bilirubin is attributed to Gilbert's Syndrome)
Alanine aminotransferase (ALT) < 2.5 x ULN
Aspartate aminotransferase (AST) < 2.5 x ULN
Total bilirubin < 2 times the upper limit of normal (unless elevated bilirubin is attributed to Gilbert's Syndrome)
Signed informed consent

Recipient Exclusion Criteria:

Prior autologous or allogeneic hematopoietic stem cell transplant
Prior malignancies, except resected non melanoma or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously is allowed. Cancer treated with curative intent < 5 years previously will not be allowed unless approved by the Protocol Officer or one of the Protocol Chairs
Active central nervous system (CNS) involvement by malignant cells
Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated
Requirement for supplemental oxygen
Uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment
History of uncontrolled autoimmune disease or on active treatment (defined as > 5 mg prednisone daily)
Seropositive for HIV 1 or 2
Seropositive for HTLV I or -II
Active Hepatitis B or C viral replication by polymerase chain reaction (PCR)
Documented allergy to iron dextran or murine proteins
Pregnant (positive serum or urine βHCG) or breastfeeding)
Females of childbearing potential (FCBP) or men who have sexual contact with FCBP unwilling to use an effective form of birth control or abstinence for one year after transplantation
Unable to comply with the treatment protocol, including appropriate supportive care, follow up and research tests.
Planned to receive post transplant maintenance therapy except for fms-like tyrosine kinase 3 (FLT3) inhibitors or BCR ABL tyrosine kinase inhibitors (TKIs).

Donor Inclusion Criteria:

HLA matched donor (matching at 8/8 antigens or alleles including HLA A, B, C, and -DRB1).
≥ 18 years to < 66.0 years
State of general good health
Completed a donor evaluation with history, medical examination and standard blood tests within 60 days of starting the hematopoietic cell collection procedure. In order to fairly represent the interests of the donor, the donor evaluation and consent will be performed by a study team member other than the recipient's attending physician.
Hepatitis A, B and C, HIV 1 and 2, HTLV, VZV, EBV, HSV, West Nile virus, Syphilis Treponema, T cruzi (Chagas), CMV, and the MPX NAT IDT (HIV/HCV/HBV) will be tested as per national standard of care guidelines for transplant donors. Donors who are HIV positive will be excluded. Donors who are positive by serology for Hepatitis B or C are eligible as long as PCR for RNA/DNA is negative
White blood cell count > 3.5 x 109/L
Platelets > 150 x 109/L
Hematocrit > 35%
Capable of undergoing leukapheresis
Able to understand and sign informed consent

Donor Exclusion Criteria:

Psychological traits or psychological or medical conditions which make them unlikely to tolerate the procedure
Pregnant or lactating female

Name	Affiliation	Role
Robert Lowsky, MD	Stanford Medical Center	Principal Investigator

Facility	Status	City	State	ZIP	Country	Contacts
Stanford Medical Center		Stanford	California	94304	United States

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	fTBI/Thiotepa/Fludarabine	Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide. CD8+ Memory T Cell Infusion: Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation Thiotepa: 5 mg/kg/day: IV for 2 consecutive days (days -6 to -5) Fludarabine: 25 mg/m2/day: IV for 5 consecutive days (days -6 to -2) Hyperfractionated TBI: Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy) Busulfan: 6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg Cyclophosphamide: 60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot_SAP	Yes	Yes	No	Study Protocol and Statistical Analysis Plan	Feb 12, 2021

Arm/Group Information

ID	Title	Description
BG000	fTBI/Thiotepa/Fludarabine	Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide. CD8+ Memory T Cell Infusion: Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation Thiotepa: 5 mg/kg/day: IV for 2 consecutive days (days -6 to -5) Fludarabine: 25 mg/m2/day: IV for 5 consecutive days (days -6 to -2) Hyperfractionated TBI: Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy) Busulfan: 6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg Cyclophosphamide: 60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg

Units	Counts
Participants	BG0007

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Number of Participants Achieving Graft-versus-Host Disease-Free and Relapse-Free Survival (GRFS) Through 1 Year Post-Transplant

The rate of participants who do not experience GvHD and also do not experience relapse are collectively considered to be GRFS. Relapse will be assessed according to the myelodysplastic syndrome or leukemia response criteria. The participants will be assessed for GRFS though 1 year post transplant. The outcome will be reported as the number of participants, a number without dispersion.

Posted

Count of Participants

Participants

1 year

ID	Title	Description
OG000	fTBI/Thiotepa/Fludarabine	Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide. CD8+ Memory T Cell Infusion: Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation Thiotepa: 5 mg/kg/day: IV for 2 consecutive days (days -6 to -5) Fludarabine: 25 mg/m2/day: IV for 5 consecutive days (days -6 to -2) Hyperfractionated TBI: Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy) Busulfan: 6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg Cyclophosphamide: 60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg

Units	Counts
Participants	OG0007

Title

Denominators

Categories

Title	Measurements
	OG0004

Secondary

Number of Participants Experiencing Graft Rejection Through 1 Year Post-Transplant

Graft rejection will be determined on the basis of reaction against the donor hematopoietic cells. The outcome will be reported as the number of participants who experience graft rejection though 1 year post transplant, a number without dispersion

Posted

Count of Participants

Participants

1 year

ID	Title	Description
OG000	fTBI/Thiotepa/Fludarabine	Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide. CD8+ Memory T Cell Infusion: Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation Thiotepa: 5 mg/kg/day: IV for 2 consecutive days (days -6 to -5) Fludarabine: 25 mg/m2/day: IV for 5 consecutive days (days -6 to -2) Hyperfractionated TBI: Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy) Busulfan: 6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg Cyclophosphamide: 60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg

Units	Counts
Participants

Secondary

Number of Participants Experiencing Acute Graft-versus-Host Disease (GvHD) Through 1 Year Post-Transplant

The participants will be assessed for acute graft versus host disease (GvHD) though 1 year post transplant. The outcome will be reported as the number of participants who experience acute GvHD, a number without dispersion.

Posted

Count of Participants

Participants

1 year

ID	Title	Description
OG000	fTBI/Thiotepa/Fludarabine	Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide. CD8+ Memory T Cell Infusion: Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation Thiotepa: 5 mg/kg/day: IV for 2 consecutive days (days -6 to -5) Fludarabine: 25 mg/m2/day: IV for 5 consecutive days (days -6 to -2) Hyperfractionated TBI: Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy) Busulfan: 6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg Cyclophosphamide: 60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg

Units	Counts
Participants

Secondary

Number of Participants With Chronic, Steroid-Requiring Graft-versus-Host Disease (GvHD) Through 1 Year Post-Transplant

The participants will be assessed for chronic, steroid requiring graft versus host disease (GvHD) though 1 year post transplant. The outcome will be reported as the number of participants who experience chronic GvHD, a number without dispersion.

The analysis population includes participants who were evaluated for chronic, steroid-requiring GvHD up to 1 year post-transplant. Of the 7 participants initially enrolled, 6 were analyzed for this outcome. One participant was excluded from the analysis due to death from acute GvHD prior to the evaluation of chronic GvHD.

Posted

Number

participants

1 year

ID	Title	Description
OG000	fTBI/Thiotepa/Fludarabine	Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide. CD8+ Memory T Cell Infusion: Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation Thiotepa: 5 mg/kg/day: IV for 2 consecutive days (days -6 to -5) Fludarabine: 25 mg/m2/day: IV for 5 consecutive days (days -6 to -2) Hyperfractionated TBI: Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy) Busulfan: 6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg Cyclophosphamide: 60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg

Secondary

Number of Participants With Non-Relapse Mortality Through 1 Year Post-Transplant Without Recurrence of Myelodysplastic Syndrome or Leukemia

Non relapse mortality will be assessed as the number of participants who have died though 1 year post transplant, without a relapse or recurrence of their myelodysplastic syndrome or leukemia. Relapse will be assessed according to the myelodysplastic syndrome or leukemia response criteria. The outcome will be reported as the number of affected participants, a number without dispersion.

Posted

Count of Participants

Participants

1 year

ID	Title	Description
OG000	fTBI/Thiotepa/Fludarabine	Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide. CD8+ Memory T Cell Infusion: Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation Thiotepa: 5 mg/kg/day: IV for 2 consecutive days (days -6 to -5) Fludarabine: 25 mg/m2/day: IV for 5 consecutive days (days -6 to -2) Hyperfractionated TBI: Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy) Busulfan: 6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg Cyclophosphamide: 60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg

Secondary

Number of Participants Who Experience Relapse Through 1 Year Post-Transplant

Relapse will be assessed according to the myelodysplastic syndrome or leukemia response criteria. The outcome will be reported as the number of participants who experience relapse though 1 year post transplant, a number without dispersion.

Posted

Count of Participants

Participants

1 year

ID	Title	Description
OG000	fTBI/Thiotepa/Fludarabine	Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide. CD8+ Memory T Cell Infusion: Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation Thiotepa: 5 mg/kg/day: IV for 2 consecutive days (days -6 to -5) Fludarabine: 25 mg/m2/day: IV for 5 consecutive days (days -6 to -2) Hyperfractionated TBI: Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy) Busulfan: 6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg Cyclophosphamide: 60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg

Units	Counts
Participants

Secondary

Overall Survival (OS)

Overall Survival (OS) will be assessed as the number of participants who remain alive at 1 year post transplant. The outcome will be reported as a number without dispersion.

Posted

Count of Participants

Participants

1 year

ID	Title	Description
OG000	fTBI/Thiotepa/Fludarabine	Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide. CD8+ Memory T Cell Infusion: Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation Thiotepa: 5 mg/kg/day: IV for 2 consecutive days (days -6 to -5) Fludarabine: 25 mg/m2/day: IV for 5 consecutive days (days -6 to -2) Hyperfractionated TBI: Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy) Busulfan: 6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg Cyclophosphamide: 60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg

Units	Counts
Participants

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	fTBI/Thiotepa/Fludarabine	Participants will be infused on Day 0 with donor derived CD34+ selected cells combined with CD8+CD45RA- T cells {CD Memory T Cells} following a standard myeloablative conditioning regimen that might consist of fTBI, Thiotepa, and Fludarabine or Busulfan and Cyclophosamide. CD8+ Memory T Cell Infusion: Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation Thiotepa: 5 mg/kg/day: IV for 2 consecutive days (days -6 to -5) Fludarabine: 25 mg/m2/day: IV for 5 consecutive days (days -6 to -2) Hyperfractionated TBI: Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy) Busulfan: 6 mg/kg/dose Q24h IV. Infused over 3 hours. 1 dose per day x 4 consecutive days x 3.6 mg/kg/dose = 14.4 mg/kg Cyclophosphamide: 60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg	1	7	1	7	5	7

Term	Organ System	Source Vocabulary	Assessment Type	Notes	Statistical Information
Steroid refractory liver GVHD	Hepatobiliary disorders		Systematic Assessment		EG0001 events1 affected7 at risk
Anal fistula	Gastrointestinal disorders		Systematic Assessment		EG0001 events1 affected7 at risk

Term	Organ System	Assessment Type	Statistical Information
Acute GvHD	Hepatobiliary disorders	Systematic Assessment	EG0003 events3 affected7 at risk
anal fistula	Gastrointestinal disorders	Systematic Assessment	EG0001 events1 affected7 at risk
elevated billirubin	Blood and lymphatic system disorders	Systematic Assessment	EG0001 events1 affected7 at risk
bacteremia	Infections and infestations	Systematic Assessment	EG0001 events1 affected7 at risk
EBV viremia	Infections and infestations	Systematic Assessment	EG0001 events1 affected7 at risk
Fungal Pneumonia	Respiratory, thoracic and mediastinal disorders	Systematic Assessment	EG0001 events1 affected7 at risk

ID	Term
D015470	Leukemia, Myeloid, Acute
D054198	Precursor Cell Lymphoblastic Leukemia-Lymphoma
D009190	Myelodysplastic Syndromes
D015464	Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ID	Term
D007951	Leukemia, Myeloid
D007938	Leukemia
D009370	Neoplasms by Histologic Type
D009369	Neoplasms
D006402	Hematologic Diseases
D006425	Hemic and Lymphatic Diseases
D007945	Leukemia, Lymphoid
D008232	Lymphoproliferative Disorders
D008206	Lymphatic Diseases
D007160	Immunoproliferative Disorders
D007154	Immune System Diseases
D001855	Bone Marrow Diseases
D009196	Myeloproliferative Disorders
D002908	Chronic Disease
D020969	Disease Attributes
D010335	Pathologic Processes
D013568	Pathological Conditions, Signs and Symptoms

ID	Term
D013852	Thiotepa
C024352	fludarabine
C042382	fludarabine phosphate
D002066	Busulfan
D003520	Cyclophosphamide

ID	Term
D063088	Phosphoramides
D009943	Organophosphorus Compounds
D009930	Organic Chemicals
D013721	Triethylenephosphoramide
D001388	Aziridines
D001389	Azirines
D006573	Heterocyclic Compounds, 1-Ring
D006571	Heterocyclic Compounds
D002072	Butylene Glycols
D006018	Glycols
D000438	Alcohols
D008698	Mesylates
D000476	Alkanesulfonates
D017738	Alkanesulfonic Acids
D000473	Alkanes
D006839	Hydrocarbons, Acyclic
D006838	Hydrocarbons
D013451	Sulfonic Acids
D013456	Sulfur Acids
D013457	Sulfur Compounds
D010752	Phosphoramide Mustards
D009588	Nitrogen Mustard Compounds
D009150	Mustard Compounds
D006846	Hydrocarbons, Halogenated